10-Apr-2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 31-Mar 4:05 PM ET)
Sarepta’s siRNA Programs Deliver High Muscle Exposure Without Toxicity in Early FSHD1 and DM1 Trials
Market Chameleon (Wed, 25-Mar 4:42 AM ET)
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Business Wire (Wed, 25-Mar 8:05 AM ET)
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Business Wire (Tue, 24-Mar 4:05 PM ET)
Market Chameleon (Fri, 20-Mar 7:19 AM ET)
Market Chameleon (Thu, 19-Mar 5:05 AM ET)
Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53
Business Wire (Thu, 19-Mar 8:30 AM ET)
Business Wire (Mon, 16-Mar 8:33 AM ET)
Business Wire (Fri, 27-Feb 9:00 AM ET)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of April 10, 2026, SRPT stock price declined to $21.18 with 1,831,140 million shares trading.
SRPT has a beta of 1.92, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.05 to the broad based SPY ETF.
SRPT has a market cap of $2.22 billion. This is considered a Mid Cap stock.
Last quarter Sarepta Therapeutics reported $443 million in Revenue and -$3.58 earnings per share. This beat revenue expectation by $45 million and missed earnings estimates by -$2.71.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJR, FBT, XBI, VTI, VB.
SRPT has underperformed the market in the last year with a price return of -57.9% while the SPY ETF gained +30.9%. SRPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.1% and +6.1%, respectively, while the SPY returned -1.8% and +7.2%, respectively.
SRPT support price is $21.03 and resistance is $23.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.
